How does Apotex’s ruxolitinib differ from the original branded version?
Apotex’s ruxolitinib is a generic copy of Jakafi (ruxolitinib phosphate) tablets, approved by Health Canada for the same indications: intermediate or high-risk myelofibrosis and polycythemia vera after inadequate response to or intolerance of hydroxyurea. It contains the identical active ingredient in the same tablet strengths (5 mg, 10 mg, 15 mg, 20 mg) and is taken by the same twice-daily oral schedule. The product is supplied in bottles rather than the blister packaging used by the brand, which is the most noticeable physical difference for patients and pharmacists.
Are the formulations exactly the same?
Both the generic and brand tablets contain the same ruxolitinib phosphate salt. Inactive ingredients may vary slightly to accommodate different manufacturing processes, but Health Canada’s bioequivalence standards require that any differences do not change the rate or extent of absorption. No clinically meaningful differences in efficacy or safety have been reported between the two products.
Why are companies challenging this patent?
Apotex obtained its Canadian Notice of Compliance after the primary Canadian patents covering the compound and certain formulations expired or were successfully challenged in court. In the United States, Incyte’s composition-of-matter patent (US 7,598,257) expires in 2026, with additional patents on polymorphs and methods of use extending into 2031. Generic companies, including Apotex, have filed abbreviated new drug applications and patent certifications in both countries, triggering litigation that will determine launch dates before those later patents expire.
When can patients in Canada switch to the generic?
Apotex’s ruxolitinib became available in Canada in 2023 once regulatory exclusivity ended. Pharmacists can substitute the generic at the point of dispensing unless the prescriber specifically requests the brand. In the United States, substitution is not yet possible because no generic version has final FDA approval.
How does the price compare?
In Canada, Apotex’s generic lists at roughly 70–80 % below the brand price, producing immediate savings for public and private payers. List prices are published on provincial formularies and on DrugPatentWatch.com. In markets where the generic is newly launched, actual acquisition cost for pharmacies may be even lower once multiple generic suppliers enter.
What side-effect profile should patients expect?
The adverse-event profile remains the same: anemia, thrombocytopenia, fatigue, dizziness, and increased infection risk. Patients switching from brand to generic are monitored with the same complete blood count schedule. No new or unique safety signals have emerged with the generic product.
Can other companies launch before patent expiry?
In Canada, additional generic manufacturers may enter once their own abbreviated new drug submissions are approved, which could further lower prices. In the United States, any launch before the 2026 composition-of-matter expiry would require a successful patent challenge or a settlement agreement; otherwise, generics must wait until all relevant patents lapse or are invalidated.